期刊文献+

他莫昔芬的药理作用与临床研究新进展 被引量:1

Research progress in the pharmacological action and clinical studies of tamoxifen
下载PDF
导出
摘要 他莫昔芬属于非甾体类雌激素类似物,临床上用于治疗雌激素受体阳性乳腺癌已有多年。他莫昔芬可在机体不同组织器官如肺部、肝脏、肾脏、骨骼肌中广泛分布,根据作用组织部位的不同,他莫昔芬具有多样化的生物效应并对多种疾病具有治疗作用。本文总结了近年来他莫昔芬治疗脑胶质瘤、杜氏肌营养不良、心血管系统疾病、双相障碍等疾病的分子机制及其临床研究进展,以期为他莫昔芬的临床合理应用提供参考。 Tamoxifen(TAM)is a nonsteroid estrogen analogue,which has been used in the treatment of estrogen receptor positive breast cancer for many years.TAM is widely distributed in different organs,such as the lung,liver,kidney and skeletal muscles.According to function on different parts of the tissue,TAM has various biological and therapeutic effects on various diseases.This paper summarized the clinical research of TAM in the treatment of glioblastoma,duchenne muscular dystrophy,cardiovascular diseases,and bipolar disorder in recent years,as well as the research progress in its molecular mechanism.This paper can provide reference for clinical rational application of TAM.
作者 向婷 张艳 朱英 张陆勇 江振洲 XIANG Ting;ZHANG Yan;ZHU Ying;ZHANG Lu-yong;JIANG Zhen-zhou(New Drug Screening Center,Jiangsu Center for Pharmacodynamics Research and Evaluation,China Pharmaceutical University,Nanjing 210009;Center for Drug Reasearch and Developmment,Guangdong Pharmaceutical University,Guangzhou 510004)
出处 《中南药学》 CAS 2021年第6期1227-1232,共6页 Central South Pharmacy
基金 国家自然科学基金面上项目(No.81773827)。
关键词 他莫昔芬 胶质瘤 肌营养不良 双相障碍 心血管事件 tamoxifen glioma duchenne muscular disease bipolar disorder cardiovascular event
  • 相关文献

参考文献5

二级参考文献38

  • 1李则挚,苑成梅,吴志国,易正辉,洪武,陈俊,王勇,胡莺燕,曹岚,黄佳,方贻儒.双相障碍抑郁发作与单相抑郁症的临床特征比较[J].上海交通大学学报(医学版),2011,31(11):1513-1517. 被引量:22
  • 2Koberle B,Tomicic MT,Usanova S,et al.Cisplatin resistance preclinical findings and clinical implications[J].BBA Rev Cancer,2010,1806(2):172-182.
  • 3Kelland L.T he resurgence of platinum-based cancer chemotherapy[J].Nat Rev Cancer,2007,7(8):573-584.
  • 4Michalke B.Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs[J].Trace Elem Med Biol,2010,24(2):69-77.
  • 5Howell SB,Safaei R,Larson CA,et al.Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs[J].Mol Pharmacol,2010,77(6):887-894.
  • 6Yamasaki M,Makino T,Masuzawa T,et al.Role of multidrug resistance protein 2(MRP2)in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma[J].Br J Cancer,2011,104(4):707-713.
  • 7Holzer AK,Manorek GH,Howell SB.Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin,carboplatin and oxaliplatin[J].Molec Pharmacol,2006,70(4):1390-1394.
  • 8Lloyd Kelland.The resurgence of platinum-based cancer chemotherapy[J].Nat Rev Cancer,2007,7(8):573-584.
  • 9Yoshimura A,Noro R,Miyanaga A,et al.Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensivestage small-cell lung cancer[J].Anticancer Res,2012,32(10):4473-4478.
  • 10Socinski M,Langer C,Okamoto I,et al.Safety and effi cacy of weekly nab-paclitaxel in combination with carboplatin as fi rst-line therapy in elderly patients with advanced non-small-cell lung cancer[J].Ann Oncol,2013,24(2):314-321.

共引文献482

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部